

10/634,419

10

PC25286A

**REMARKS**

Claims 1 and 7 to 13 are pending in the application.

Claims 1 is currently amended.

Claims 7 to 9, 11, and 13 were previously presented.

Claims 2 to 6 are canceled.

***Amendments to the Claim(s)***

Claim 1 is amended to delete the definitions of the groups L, R<sup>5</sup>, R<sup>6</sup>, C<sub>8</sub>-C<sub>10</sub> bicycloalkyl, and 8- to 10-membered heterobicycloalkyl, which became unnecessary when the definition of groups R<sup>1</sup> and Q were amended in Applicants' previous paper.

***Claim Rejections – 35 USC § 112***

In the Office Action, claims 1, 10, and 12 are rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. It was argued that variable group L in claim 1 renders claim 1 and its dependent claims 10 and 12 unclear because claim 1 appears to have no variable L.

Applicants traverse the rejection because claim 1 is now amended to delete group L. Accordingly, Applicants believe that claim 1 and dependent claims 10 and 12 are definite and patentable under 35 U.S.C. § 112, second paragraph.

***Allowable Subject Matter***

Applicants note that claims 7 to 9 and 11 to 13 are allowed.

***Conclusion***

In view of the above amendment and remarks, Applicants believe that the rejection is overcome and request reconsideration of claims 1, 10, and 12.

10/634,419

11

PC25286A

Respectfully submitted,

Date: April 20, 2006

Claude F. Purchase, Jr.  
Claude F. Purchase, Jr.  
Reg. No. 47,871  
Pfizer Inc.  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Tel. (734) 622-1692  
Fax (734) 622-1553